Reference entry · D-retro-inverso senolytic peptide
FOXO4-DRI
Also known as: FOXO4-D-Retro-Inverso · senolytic FOXO4 peptide
- Class
- D-retro-inverso senolytic peptide
- Primary targets (literature)
- FOXO4–p53 interaction (senescent cell clearance literature)
- Regulatory context
- Investigational — not FDA-approved. Senolytic preclinical findings do not establish safety or efficacy in humans.
Overview
FOXO4-DRI is a D-retro-inverso peptide designed to disrupt FOXO4–p53 interactions in senescent cells. It sits at the intersection of senolytic research and catalog peptide supply, where sequence fidelity is critical.
Mechanism in research literature
Proposed mechanism centers on competitive disruption of FOXO4–p53 binding in senescent cells, triggering apoptosis in preclinical models while sparing proliferating cells in published assays.
Common research focus areas
- Senescent cell clearance in rodent models
- FOXO4–p53 interaction biochemistry
- D-retro-inverso peptide synthesis and stability
- Independent replication of senolytic endpoints
Full literature roundup
Read the cited research summary
A D-retro-inverso peptide studied for senescent cell clearance in preclinical models. What the senolytic literature reports — and where human evidence stops.
FOXO4-DRI research roundup · 6 minEvaluate catalog material
- COA literacy — read batch documentation before comparing vendors.
- Peptide identity testing — why sequence confirmation matters beyond purity %.
- How we vet sources — our score methodology for recommended vendors.